Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2024.11.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk-directed management of chronic kidney disease.
Nat Rev Nephrol
January 2025
New York University Grossman School of Medicine, New York, NY, USA.
The timely and rational institution of therapy is a key step towards reducing the global burden of chronic kidney disease (CKD). CKD is a heterogeneous entity with varied aetiologies and diverse trajectories, which include risk of kidney failure but also cardiovascular events and death. Developments in the past decade include substantial progress in CKD risk prediction, driven in part by the accumulation of electronic health records data.
View Article and Find Full Text PDFUnlocking insights: Clinical associations from the largest 6-minute walk test collection via the my Heart Counts Cardiovascular Health Study, a fully digital smartphone platform.
Prog Cardiovasc Dis
January 2025
Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Wu Tsai Human Performance Alliance, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Digital Health, Stanford University School of Medicine, Stanford, CA 94305, USA; Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:
Background: The six-minute walk test (6MWT) is a prognostic sub-maximal exercise test used clinically as a measure of functional capacity. With the emergence of advanced sensors, 6MWTs are being performed remotely via smartphones and other devices. The My Heart Counts Cardiovascular Health Study is a smartphone application that serves as a digital platform for studies of human cardiovascular health, and has been used to perform 30,475 6MWTs on 8922 unique participants.
View Article and Find Full Text PDFImproving myocardial infarction diagnosis with Siamese network-based ECG analysis.
PLoS One
January 2025
School of Computer Science & Engineering (SCOPE), VIT-AP University, Amaravati, Andhra Pradesh, India.
Background: Heart muscle damage from myocardial infarction (MI) is brought on by insufficient blood flow. The leading cause of death for middle-aged and older people worldwide is myocardial infarction (MI), which is difficult to diagnose because it has no symptoms. Clinicians must evaluate electrocardiography (ECG) signals to diagnose MI, which is difficult and prone to observer bias.
View Article and Find Full Text PDFComparison of the 2023 ISCVID and ESC Duke clinical criteria for the diagnosis of infective endocarditis among patients with positive blood cultures for new typical microorganisms.
Infection
January 2025
Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland.
Purpose: To evaluate the performance of the Duke clinical criteria of the European Society of Cardiology (ESC; 2015 and 2023 versions) and the 2023 International Society for Cardiovascular Infectious Diseases (ISCVID) in diagnosing infective endocarditis (IE) among patients with bacteraemia/candidaemia by pathogens introduced for the first time as typical microorganisms by ISCVID.
Methods: Retrospective study.
Setting: This study included adult patients with bacteraemia/candidaemia by such pathogens (coagulase negative staphylococci, Abiotrophia spp.
Sodium zirconium cyclosilicate for MRAs optimization in HFrEF: lessons learned from the REALIZE-K trial.
Heart Fail Rev
January 2025
Centre d'Investigations Cliniques Plurithématique 1433 and INSERM U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Institut Lorrain du Coeur Et Des Vaisseaux, CHRU de Nancy, Université de Lorraine, Nancy, France.
Mineralocorticoid receptor antagonists (MRAs) are a cornerstone of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF), offering significant benefits in reducing mortality and hospitalizations. However, their use is often constrained by the risk of hyperkalemia, particularly in patients with chronic kidney disease. Patiromer and sodium zirconium cyclosilicate (SZC), two novel potassium binders, have emerged as highly effective and safe tools for managing hyperkalemia and enabling the optimization of MRA therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!